FREE Shipping on orders over $200 USD

Email

support@elyxaminos.com

My Account
BPC-157 10mg
BPC-157 10mg - Image 2
BPC-157 10 mg - 3D vial rendering

BPC-157 10mg

$ 84,12

Gastric Pentadecapeptide · Angiogenesis · Tendon and Ligament · Research Only

  • BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protective sequence of human gastric juice.
  • Preclinical literature describes multiple pathways of action documented in animal models: upregulation of VEGFR2 with an angiogenic effect; activation of the Akt-eNOS and Src-Caveolin-1-eNOS cascades on vasomotor tone; and an increase in the growth hormone receptor in tendon fibroblasts with in vitro tendinocyte proliferation (Hsieh et al., Sci Rep 2020 PMC7555539; Chang et al., J Appl Physiol 2011).
  • Presentation 10 mg lyophilized lyophilized For research purposes only

In stock

Global Elite Shipping

Fast shipments from our logistics center in the USA to worldwide.

Guaranteed Purity

Each batch includes a Certificate of Analysis (COA) for research grade.

Secure & Private Payment

Encrypted transactions to protect your cellular health investment.

Description

BPC-157 10mg

Gastric Pentadecapeptide · Angiogenesis · Tendon and Ligament · Research Only

What is it and how does it work?

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protective sequence of human gastric juice. Preclinical literature describes multiple documented pathways of action in animal models: upregulation of VEGFR2 with an angiogenic effect, activation of the Akt-eNOS and Src-Caveolin-1-eNOS cascades on vasomotor tone, and an increase in growth hormone receptor in tendon fibroblasts with in vitro tenocyte proliferation (Hsieh et al., Sci Rep 2020 PMC7555539; Chang et al., J Appl Physiol 2011).

Extensive preclinical evidence (Sikiric et al., University of Zagreb, since the 90s) in mouse and rat models: Achilles tendon healing, collateral ligament, gastric mucosa, intestinal anastomosis, and ulcerative colitis (PL-14736, Pliva Phase II trials). A systematic review from 2025 (Vasireddi et al., Am J Sports Med 2025 PMID 40756949) of 36 studies documents reduction in pro-inflammatory cytokines and modulation of tissue repair pathways in experimental models. No human use approved by FDA — research material only.

Reconstitution and dosage

  • Vial 10 mg lyophilized
  • Bacteriostatic water: 2 ml (standard rule: 1ml per 5mg)
  • Resulting concentration: 5,000 mcg/mL
  • Per unit U-100: 50 mcg · verification: 5,000 ÷ 100 = 50 mcg/u ✓
  • Conservation Refrigerate at 2–8°C · Use within 28–30 days
  • Performance Equivalent volume: 200 U-100 units per reconstituted vial

Volume Conversion Chart (U-100 syringe)

U-100 equivalent Volume Load (mcg) Verification
5 u 0.05 mL 250 micrograms 5 u × 50 mcg = 250 mcg ✓
10 units 0.10 mL 500 mcg 500 mcg
15 years old 0.15 milliliters 750 mcg 750 mcg
20 u 0.20 mL 1,000 mcg 20 units × 50 mcg = 1,000 mcg ✓

Documented evidence in research literature

Preclinical Evidence · Tendon and Ligament Healing
  • Staresinic et al., J Orthop Res 2003 — rat Achilles tendon transected, 10 mcg/kg IP/PO → accelerated healing
  • Krivic et al., J Orthop Res 2006 (PMID 16583442) — Tendon-bone detachment model, BPC-157 rescues healing and counteracts deleterious effect of corticosteroids
  • Cerovecki et al., J Orthop Res 2010 — medial collateral ligament tear in rats; BPC-157 improves ligament healing
  • Vasireddi et al., Am J Sports Med 2025 (PMID 40756949) — systematic review of 36 preclinical studies confirms modulation of pro-inflammatory cytokines
Preclinical evidence · gastric and GI mucosa
  • Sikiric et al., Inflammopharmacology 2006 — PL-14736 (BPC-157) in early phase II trials for ulcerative colitis (Pliva, Croatia) in animal and exploratory human models
  • Multiple models of gastritis, esophagitis, and intestinal mucosal damage documented protection and repair in rodents
  • Typical preclinical ranges: 10 mcg/kg–10 µg/kg intraperitoneal or subcutaneous administration
Documented molecular mechanism
  • Hsieh et al., Sci Rep 2020 PMC7555539 — Src-Caveolin-1-eNOS activation in vitro
  • Sikiric et al., Curr Pharm Des 2018 (PMID 29737246) — bidirectional modulation of the NO/L-arginine system
  • Chang et al., J Appl Physiol 2011 — upregulation of GH receptor in tendon fibroblasts
  • Structural stability reported under gastric conditions—property used as justification for oral exploration in preclinical studies

Combinations reported in literature

  • BPC-157 + TB-500 (preclinical literature ‘Wolverine’ stack): independent pathways — BPC-157 via VEGFR2/eNOS contributes to angiogenesis; TB-500 (Ac-SDKP sequence) contributes to cell migration. No reported mechanistic redundancy.
  • BPC-157 + Tesamorelin/CJC-Ipa in regeneration studies: endogenous GH amplifies GH receptor upregulation that BPC-157 produces in tendon fibroblasts in experimental models.
  • BPC-157 + GHK-Cu: act on different compartments according to the literature—BPC-157 in deep tissue (tendons, ligaments, mucosa); GHK-Cu in skin, fascia, and the extracellular matrix.
  • BPC-157 + KPV: Both modulate anti-inflammatory pathways via distinct mechanisms in preclinical models—KPV via melanocortin MC1R; BPC-157 via NO/cytokines.

Practical notes

  • Presentation 10mg allows for extended research without frequent vial replacement. Vial yield: 200 units total U-100.
  • Documented via primary preclinical literature: SC and IP in rodents. Reported gastric stability also allows for oral exploration in preclinical studies.

Contraindications and precautions

  • Research material only. Not FDA-approved for human use. No established human safety data. Preclinical literature reports theoretical caution in models with active cancer due to VEGF upregulation. Do not use in humans.

Research material only. Not approved for human use by the FDA. This product is intended for scientific research purposes in controlled laboratory settings only. It is not a drug. Not for human or animal administration, therapeutic use, or diagnostic use.

Research material only. It is not a medication. Not for human or animal use, not for diagnostic or therapeutic use.

Related products

Select your currency
COP Colombian peso
USD United States (US) dollar

Legal Notice

All products are sold in powder (lyophilized) form and require reconstitution with a suitable diluent for research purposes only. Laboratory supplies (e.g., syringes, bacteriostatic water, etc.) are not included. Dosage instructions are not provided.

We comply with all local and national laws and regulations related to product sales. exclusively for research.
We are not a pharmacy, nor do we offer, promote, or provide any advice for human or animal consumption.

Please carefully review our Terms and Conditions Before making a purchase on our website.

You must be over 21 years old and a licensed research professional.

When clicking on “I accept”, you confirm that you have read and accepted the Terms and Conditions set forth above.

I accept
x
Cart
Your cart is empty
Let's go shopping!
Start shopping